REGULATORY

• Revolade, Bilanoa See First Generics in June Listing; 3 Final AGs on Roster
  June 11, 2026

• Official Hints at Potential Change to Growth Target in Draft Roadmap
  June 11, 2026

• Ishin Proposes Adding Drug, Device Makers to Chuikyo, LDP Wary
  June 10, 2026

• Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
  June 10, 2026

• LDP Lawmakers Seek Routine HPV Vaccinations for Males by April 2027
  June 10, 2026

• LDP Team Seeks Minister-Led AI Task Force at MHLW
  June 10, 2026

• MHLW to Continue Reviewing Tavneos Safety Measures: Official
  June 10, 2026

• ONODERA GT’s Parkinson’s Gene Therapy Gets Sakigake Tag
  June 10, 2026

• MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
  June 9, 2026

• Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
  June 9, 2026

• Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
  June 8, 2026

• Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
  June 8, 2026

• Japan Tightens Oversight of Mounjaro Resales: Health Minister
  June 8, 2026

• LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
  June 5, 2026

• Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
  June 5, 2026

• Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
  June 4, 2026

• LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
  June 4, 2026

• LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
  June 3, 2026

• Three Sent to Prosecutors over Alleged Illegal Mounjaro Sales
  June 3, 2026

• LDP Group Eyes Proposal to Address Challenges in Radiopharmaceutical Use
  June 3, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »